Groundwork establishing HH signaling as a therapeutic target in AML include multiple studies investigating the expression of HH components in primary patient-derived whole mononuclear leukemic cells, CD34+ cells and/or bone marrow tissue. Here, CD34 is linked to acute myeloid leukemia.